ADURO BIOTECH, INC. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (33)

View All

Latest Posts

About This Stock More About This Stock
Morning Call For Tuesday, March 6
Article By: Jim Van Meerten
Tuesday, March 6, 2018 8:50 AM EDT
Mar E-mini S&Ps (ESH18 +0.43%) this morning are up +0.46% and European stocks are up +0.92% on signs the U.S. may not go through with plans to put tariffs on metal imports.
In this article: ADM, BG, DPZ, JWN, NLS, TGT, QDEL, ALOG, GLYC, ADRO, FATE, SNDX, FRPT, GTHX, TNTR
Read
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EDT
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read
Teva's Drug Austedo FDA Nod For Label Expansion In Dyskinesia
Article By: Zacks Investment Research
Thursday, August 31, 2017 3:29 PM EDT
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved a label expansion for its drug, Austedo.
In this article: TEVA Also: ALXN, REGN, ADRO
Read
Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval
Article By: Zacks Investment Research
Thursday, August 31, 2017 2:58 PM EDT
Novartis AG announced that the FDA has approved its breakthrough gene transfer treatment - CAR-T Therapy Kymriah.
In this article: NVS Also: GILD, KITE, ADRO
Read
Anthera's Blisibimod Positive In Phase II Extension Study
Article By: Zacks Investment Research
Tuesday, August 29, 2017 1:43 PM EDT
Anthera Pharmaceuticals, Inc. announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA nephropathy (IgAN).
In this article: ANTH Also: LLY, ACAD, ADRO
Read
All Posts

Latest Tweets for $ADRO

No tweets yet!

PARTNER HEADLINES